RSS Feeds
Anaphylactoid Reactions Reported after Treatment with Ciprofloxacin
- Harold Davis, MD;
- Ermona McGoodwin, BS; and
- T. Greene Reed, MD, MPH
Excerpt
Ciprofloxacin (Cipro, Miles Inc., West Haven, Connecticut) is a fluorinated quinolone that is a broad-spectrum antibacterial agent. It is recommended for the treatment of infections caused by susceptible bacteria in lower respiratory infections, skin and skin-structure infections, bone and joint infections, urinary-tract infections, and infectious diarrhea. Recommended adult dosages range from 250 mg every 12 hours (for mild urinary-tract infections) to 750 mg every 12 hours (for more severe or complicated infections). Ciprofloxacin oral tablets have been approved for marketing in the United States since October 1987; the drug should not be used in children or pregnant women. Like other
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
From the Food and Drug Administration, Rockville, Maryland. For current author addresses, see end of text.
-
The use of trade names is for purposes of product identification only and is not intended as product endorsement by the Food and Drug Administration or the Department of Health and Human Services. The opinions in this paper are those of the authors and not necessarily those of the Food and Drug Administration.
-
Requests for Reprints: Harold Davis, MD, Office of Epidemiology and Biostatistics, Food and Drug Administration, 5600 Fishers Lane, HFD-730, Rockville, MD 20857.
-
Current Author Addresses: Dr. Davis: National Center for Health Statistics, Division of Health Examination Statistics, Center Building, Room 2-58 3700 East-West Highway, Hyattsville, MD 20782.
Ms. McGoodwin: Office of Epidemiology and Biostatistics, Food and Drug Administration, 5600 Fishers Lane, HFD-730, Rockville, MD 20857.
Dr. Reed: Division of Anti-Infective Drug Products, Food and Drug Administration, 5600 Fishers Lane, HFD-520, Rockville, MD 20857.
